Eisai Company, Ltd. Resubmits Supplemental New Drug Application For Aricept, Alzheimers Disease Drug, To FDA

Tokyo (JCN) Dec 21, 2005 - Eisai has announced that its US subsidiary Eisai Medical Research resubmitted a supplemental new drug application (sNDA) for Aricept, the company’s proprietary agent for treating severe Alzheimer’s disease, to the US Food and Drug Administration (FDA) as of December 16.

MORE ON THIS TOPIC